• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Bone
Tag:

Bone

Health

Calcium and vitamin D supplements show limited fracture prevention benefits

by Chief Editor May 21, 2026
written by Chief Editor

Beyond the Supplement Bottle: The Future of Bone Health and Fall Prevention

For decades, the standard advice for aging adults has been simple: take calcium and vitamin D to keep your bones strong and avoid fractures. It became a routine part of healthcare, with prescriptions and over-the-counter sales climbing steadily. However, a seismic shift is occurring in how we approach geriatric wellness.

Recent evidence published in The BMJ has challenged the long-held belief that routine supplementation is the key to preventing falls and fractures. After reviewing 69 randomised controlled trials involving 153,902 adults, researchers found that calcium, vitamin D, or a combination of both offered little to no clinically meaningful benefit for the majority of older people.

Did you know? Almost a third of people aged 65 and older experience a fall each year. These events often lead to fractures that can significantly reduce quality of life and increase the need for residential care.

The Shift Toward Functional Movement

As the limitations of supplements become clearer, the medical community is pivoting toward “functional” prevention. The data suggests that the future of bone health isn’t found in a pill, but in movement. Rather than focusing on the chemical composition of the bone, the trend is moving toward the stability of the body.

The Shift Toward Functional Movement
Bone

We are seeing a redirected focus toward interventions that have a proven track record of success, specifically:

  • Resistance Exercise: Weight-bearing activities that challenge the muscles and bones.
  • Balance Training: Targeted exercises designed to reduce the likelihood of a fall occurring in the first place.
  • Combined Modalities: Programs that integrate physical activity with education and hazard assessment.

The goal is moving from “bone density” to “fall resilience.” It is one thing to have strong bones; it is another to have the balance and strength to ensure those bones never hit the ground.

Pro Tip: The “Safe Home” Audit

Prevention starts with your environment. Conduct a “hazard assessment” of your living space. Remove loose rugs, improve lighting in hallways, and install grab bars in bathrooms. These simple environmental changes often provide more immediate protection than a daily supplement.

Personalized Medicine vs. Routine Supplementation

One of the most critical takeaways from the BMJ review is that “routine” supplementation—giving the same advice to everyone—is likely ineffective. The researchers noted that their findings may not apply to individuals with specific bone disorders or those already receiving drug treatments for osteoporosis.

View this post on Instagram about Personalized Medicine, Routine Supplementation One
From Instagram — related to Personalized Medicine, Routine Supplementation One

The future of bone health is precision medicine. Instead of a blanket recommendation, we are moving toward a model where supplementation is targeted based on:

  • Specific medical diagnoses (such as severe osteoporosis).
  • Individual deficiency levels confirmed by clinical testing.
  • Interaction with existing pharmaceutical treatments.

This approach ensures that those who truly need these nutrients receive them, while the general population avoids unnecessary supplements that provide no meaningful benefit.

The Impact on Clinical Guidelines and Public Health

The discrepancy between current guidelines and recent evidence is stark. Despite a lack of consistent results in previous reviews, many regulatory agencies and clinicians continue to recommend vitamin D and calcium. This creates a “guideline gap” that is now being addressed.

The call to action for guideline panels is clear: re-evaluate general recommendations. We can expect a transition where public health funding is redirected from supplement promotion toward community-based exercise programs and tailored risk assessments.

By shifting the focus from the pharmacy to the gym and the home, healthcare systems can better address the global public health priority of reducing fracture-related injuries.

Expert Insight: The evidence from 36 trials involving 92,045 participants showed high certainty that vitamin D supplements alone had little to no effect on preventing fractures. When combined with calcium (across 15 trials and 51,126 participants), the result remained the same. This suggests that the synergy we once hoped for between these two nutrients may not translate into actual fracture prevention for the average older adult.

Common Questions About Bone Health and Supplements

Do I need to stop taking my calcium or vitamin D supplements?

You should never stop a prescribed medication or supplement without consulting your doctor. While routine supplementation may not prevent falls for most people, those with specific bone disorders or those on osteoporosis medication may still require them.

Common Questions About Bone Health and Supplements
Vitamin supplements

What is the best way to prevent fractures in older age?

The most effective strategies currently include a combination of balance and resistance exercises, along with home safety assessments to remove fall hazards.

Are there any benefits to calcium and vitamin D at all?

These nutrients are essential for the body, but the recent focus is on whether supplementing them beyond a healthy diet actually prevents the specific outcomes of falls and fractures in the general older population.

Why are supplements still recommended if the evidence is unclear?

Medical guidelines often take time to update. However, researchers are now urging regulatory agencies to align their recommendations with the latest high-certainty evidence.

What are your thoughts on the shift from supplements to exercise for bone health? Have you noticed a change in the advice you receive from your healthcare provider? Let us know in the comments below or subscribe to our newsletter for more evidence-based health updates.

May 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Maternal antibodies provide lifelong protection against adult gum disease

by Chief Editor April 29, 2026
written by Chief Editor

The Hidden Legacy of Motherhood: How Prenatal Immunity Shapes Lifelong Oral Health

A mother’s influence extends far beyond genetics and nurturing; it appears to lay the very foundation for her child’s oral health, protecting against gum disease decades later. New research from the Hebrew University of Jerusalem reveals that maternal antibodies, transferred both in utero and through breastfeeding, actively “program” a child’s immune system to fight off oral diseases, including periodontitis.

View this post on Instagram about The Hidden Legacy of Motherhood, Hebrew University of Jerusalem
From Instagram — related to The Hidden Legacy of Motherhood, Hebrew University of Jerusalem

The Two Pathways of Maternal Immunity

The study, published in Nature Communications, highlights two distinct pathways through which mothers provide this crucial immune support. The first, and arguably most impactful, involves the transfer of IgG antibodies during pregnancy. These antibodies travel to the newborn’s salivary glands, where they are secreted into saliva, essentially training the immune system to distinguish between harmless bacteria and potential threats.

Prof. Avi-Hai Hovav and DMD/PhD student Reem Naamneh, who led the research at the Faculty of Dental Medicine at Hebrew University, discovered that offspring lacking these prenatal antibodies exhibited a hyper-activated immune response and increased bacterial loads in their gums. This early immune misstep translated to a significantly higher susceptibility to periodontitis in adulthood – a condition marked by inflammation and bone loss around the teeth.

Beyond Initial Protection: Breastfeeding’s Role in Oral Barrier Development

While prenatal antibodies establish the immune “tone,” antibodies delivered through breast milk play a different, yet equally vital, role. The research demonstrates that postnatal antibodies are essential for the proper maturation of the oral epithelium – the protective lining of the mouth. These antibodies regulate the timing of “barrier sealing,” ensuring the mouth’s defenses are fully formed at the appropriate moment.

Beyond Initial Protection: Breastfeeding’s Role in Oral Barrier Development
Breastfeeding Pasteurellaceae Oral Barrier Development While

Disrupting this process, for example, with antibiotics, compromises the integrity of the oral barrier, leaving it vulnerable to infection. This highlights the delicate interplay between the microbial environment and the development of a robust oral defense system.

Targeting Specific Pathogens: Pasteurellaceae and Gum Disease

The team’s investigation pinpointed specific oral pathogens targeted by maternal IgG antibodies. They found that these antibodies recognize and bind to members of the Pasteurellaceae family, bacteria known to contribute to aggressive forms of gum disease. This discovery is a significant step towards understanding the origins of oral diseases and identifying potential intervention points.

Why Are Maternal Antibodies Vital For Newborn Flu Protection? – Influenza Relief Guide

The Future of Preventive Dentistry: Maternal Immunization?

The findings open exciting possibilities for preventive strategies. Researchers suggest that vaccinating mothers during pregnancy could enhance the transfer of specific antibodies to their children, effectively pre-programming their immune systems to resist chronic oral infections. This proactive approach could dramatically reduce the incidence of periodontitis and other oral health issues in future generations.

Did you know? The foundations of a healthy adult smile are being laid even before a baby’s first tooth emerges.

The Expanding Landscape of Maternal Immunity Research

This research builds upon a growing body of evidence demonstrating the profound and lasting impact of maternal immunity on various aspects of a child’s health. Studies have shown links between maternal antibodies and protection against allergies, autoimmune diseases, and even certain cancers. The oral microbiome, and its connection to systemic health, is increasingly recognized as a critical area for investigation.

The Expanding Landscape of Maternal Immunity Research
Immunity Breastfeeding

Pro Tip: Maintaining excellent oral hygiene during pregnancy is crucial, not only for the mother’s health but also for establishing a healthy oral microbiome for the developing child.

FAQ

Q: How long does maternal antibody protection last?
A: The study suggests lifelong protection against adult gum disease, though the duration and effectiveness can vary.

Q: Can breastfeeding compensate for a lack of prenatal antibodies?
A: Breastfeeding provides essential antibodies for oral barrier development, but it doesn’t fully replicate the immune “programming” effect of prenatal IgG transfer.

Q: Is maternal immunization currently available?
A: Maternal immunization for oral health is still in the research phase, but the findings suggest it’s a promising avenue for future preventive strategies.

Q: What is periodontitis?
A: Periodontitis is a serious gum infection that damages the soft tissue and bone that support teeth. It can lead to tooth loss.

This research underscores the remarkable power of maternal immunity and its lasting impact on a child’s health. As we continue to unravel the complexities of the oral microbiome and the immune system, we move closer to a future where preventive strategies can ensure a lifetime of healthy smiles.

Want to learn more about oral health? Explore our articles on gum disease prevention and the oral microbiome.

April 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Researchers uncover new mechanism linking metabolism, immunity, and skeletal health

by Chief Editor April 25, 2026
written by Chief Editor

Rethinking the “Heavy Bone” Myth: The Hidden Cost of Obesity

For years, a common belief in skeletal biology was that higher body weight actually benefited bone health. The logic was simple: increased mechanical loading from extra weight should, in theory, strengthen the skeleton. However, groundbreaking research is now flipping this narrative on its head.

We now realize that obesity doesn’t just put physical pressure on joints; it fundamentally reshapes the internal environment of the bone marrow. This shift transforms the marrow from a supportive niche into a driver of bone degradation, challenging everything we thought we knew about the relationship between weight and skeletal integrity.

Did you know? Bone marrow adipose tissue (BMAT) is not just passive fat storage. It is an active endocrine organ that can secrete signaling molecules to regulate both your immune system and your bone density.

The Biological Trigger: How Bone Marrow Fat Destroys Bone

The mechanism behind this bone loss is a complex chain reaction. In obese conditions, bone marrow adipocytes (fat cells) expand rapidly. These expanded cells increase the production of a signaling molecule called MCP-1.

View this post on Instagram about Bone, Future
From Instagram — related to Bone, Future

MCP-1 acts as a beacon, recruiting myeloid immune cells and steering them toward an immunosuppressive state. These cells begin expressing PD-L1 (programmed death-ligand 1). Even as these PD-L1+ cells suppress T-cell activity—potentially explaining why obesity is linked to reduced vaccine effectiveness and higher infection risks—they do something far more damaging to the skeleton.

These PD-L1-expressing cells interact with PD-1 receptors on osteoclast precursors. This specific interaction promotes the differentiation of these precursors into mature osteoclasts—the specialized cells responsible for resorbing and degrading mineralized bone matrix. The result is a significant loss of both trabecular and cortical bone volume.

For more on how metabolic health affects the body, witness our guide on metabolic health and systemic inflammation.

Future Therapeutic Trends: Repurposing Cancer Drugs for Bone Health

One of the most exciting prospects arising from this research is the potential to repurpose existing medical technology. The PD-1/PD-L1 axis is already a primary target in cancer immunotherapy. This suggests a future where immune checkpoint inhibitors could be adapted to treat obesity-related bone disorders.

Targeting the JNK Pathway

Recent data indicates that PD-1/PD-L1 inhibitors can exert direct effects on bone metabolism. By inhibiting the JNK pathway, these agents may reduce the proliferation and resorptive capacity of osteoclasts, effectively slowing down bone loss.

Pharmacological Blockade

Research has shown that blocking the PD-1/PD-L1 signaling axis during the early stages of osteoclast precursor development can mitigate bone resorption. This opens the door for targeted pharmacological interventions that preserve bone integrity without needing to address total body weight first.

Pharmacological Blockade
Bone Future Health
Pro Tip: Future treatment for obesity-related osteoporosis may require a multidisciplinary approach, combining the expertise of endocrinologists, immunologists, and bone specialists to manage the intersection of metabolism and immunity.

The Broader Impact: Immunity and Skeletal Health

The discovery of this link suggests that the skeleton is far more integrated with the immune system than previously realized. The expansion of bone marrow fat creates an “immunosuppressive microenvironment” that disrupts the delicate immune equilibrium.

This suggests that treating bone loss in obese patients isn’t just about calcium or vitamin D; it’s about managing the immune checkpoint pathways. By reducing bone marrow adipogenesis—as seen in studies using BMAd-Pparg KO models—researchers have successfully reduced the number of PD-L1+ myeloid cells and improved bone structure.

Check out our related article on how immune checkpoints regulate the body to learn more about PD-L1.

Frequently Asked Questions

What is the role of MCP-1 in bone loss?

MCP-1 is a chemokine secreted by expanded bone marrow fat in obese individuals. It recruits myeloid immune cells and promotes their expression of PD-L1, which eventually drives the formation of bone-resorbing osteoclasts.

Frequently Asked Questions
Bone Future

Can PD-1/PD-L1 inhibitors actually help bones?

Yes, evidence suggests that blocking this pathway can reduce osteoclast proliferation and resorptive activity, potentially protecting bone volume in the context of obesity.

Why does obesity lead to weaker bones if weight usually strengthens them?

While mechanical loading is beneficial, the metabolic changes caused by obesity—specifically the expansion of bone marrow fat—trigger an immune response that accelerates bone resorption, outweighing the benefits of the extra weight.

Does bone marrow fat affect the rest of the immune system?

Yes. The PD-L1+ myeloid cells recruited by bone marrow fat suppress T-cell activity, which may contribute to impaired immune responses, such as decreased vaccine effectiveness.

Join the Conversation

Do you think immune-based therapies will turn into the new standard for treating osteoporosis? Let us know your thoughts in the comments below or subscribe to our newsletter for the latest breakthroughs in metabolic medicine!

April 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Long-term study supports tenofovir alafenamide for chronic hepatitis B

by Chief Editor April 24, 2026
written by Chief Editor

The Shift Toward Long-Term Safety in Hepatitis B Care

For years, managing chronic hepatitis B (CHB) has been a balancing act between suppressing the virus and managing the side effects of medication. Recent long-term data is now highlighting a significant trend: the transition toward treatments that prioritize not just viral suppression, but the preservation of organ health over decades.

The focus is increasingly shifting toward Tenofovir alafenamide (TAF), a nucleoside reverse transcriptase inhibitor (NRTI) designed to decrease the amount of hepatitis B virus (HBV) in the blood. While earlier treatments were effective, the long-term impact on bone and kidney health has become a primary concern for clinicians, especially as the patient population ages.

Did you recognize? TAF belongs to a class of medications called NRTIs. While these drugs are highly effective at reducing the viral load in the blood, they are not a cure for hepatitis B and may not prevent the spread of the virus to others.

Prioritizing Bone and Kidney Health

One of the most critical trends in HBV therapy is the move away from medications that cause gradual decline in renal function and bone density. In a comprehensive eight-year analysis of Chinese participants, TAF demonstrated a superior safety profile compared to tenofovir disoproxil fumarate (TDF).

Prioritizing Bone and Kidney Health
Tenofovir Prioritizing Bone and Kidney Health One The Impact of Switching Treatments

Data shows that in patients taking TAF, the estimated glomerular filtration rate (eGFR)—a key measure of kidney function—and bone mineral density in the hip and spine remained stable over the eight-year period. What we have is a vital development for aging populations who are already at a higher risk for osteoporosis and kidney dysfunction.

The Impact of Switching Treatments: Reversibility and Recovery

A pivotal discovery in recent research is the potential for recovery when switching from TDF to TAF. For patients who experienced small declines in renal and bone parameters during TDF treatment, these markers showed improvement after switching to an open-label TAF regimen.

View this post on Instagram about The Impact of Switching Treatments, Reversibility and Recovery
From Instagram — related to The Impact of Switching Treatments, Reversibility and Recovery

This suggests a future where “treatment switching” becomes a standard protocol to mitigate long-term toxicity. By transitioning patients to TAF, healthcare providers can maintain high rates of viral suppression while actively improving the patient’s overall physiological health.

Pro Tip: Consistency is key. Because stopping TAF can cause the HBV condition to suddenly worsen, it is essential to take the medication exactly as directed, typically once daily with food, and to never miss a dose.

Understanding Viral Suppression and Resistance

The effectiveness of TAF remains robust over the long term. In studies excluding missing data, viral suppression rates (HBV DNA < 29 IU/mL) reached 95.2% for those on a consistent TAF regimen and 95.5% for those who switched from TDF to TAF at the eight-year mark.

#2 – One Year Outcome of Bictegravir/Emtricitabine/Tenofovir Alafenamide (…) – Carina A. Rodriguez

Perhaps most importantly for the future of HBV treatment, no resistance to TAF was detected during these long-term observations. This lack of resistance, combined with high alanine aminotransferase normalization rates, reinforces TAF’s position as a preferred long-term option for maintaining liver health.

For more information on drug classifications, you can explore resources like MedlinePlus to understand how NRTIs function.

Frequently Asked Questions

Does TAF cure hepatitis B?
No, Tenofovir alafenamide (TAF) does not cure hepatitis B, though it is used to treat the chronic infection by decreasing the amount of HBV in the blood.

What is the typical dose for adult patients with compensated liver disease?
TAF is indicated for adult patients with chronic HBV infection and compensated liver disease at an oral dose of 25 mg taken once daily.

Can I stop taking TAF if I experience better?
No. You should continue taking TAF even if you feel well. Stopping the medication can cause your condition to worsen suddenly, and doctors typically order regular lab tests for several months after any cessation of treatment.

Is TAF safer for the kidneys than TDF?
Yes, evidence suggests TAF has improved renal and bone safety compared to TDF, with stable eGFR and bone mineral density observed over long-term use.

What are your thoughts on the evolution of HBV treatments? Have you or a loved one experienced the transition between different antiviral therapies? Share your experiences in the comments below or subscribe to our newsletter for the latest updates in hepatology.

April 24, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

BMI increases in early childhood may reflect muscle growth, not fat

by Chief Editor April 16, 2026
written by Chief Editor

Rethinking Childhood Obesity: Why BMI Alone Isn’t Enough

For decades, the body mass index (BMI) has been a primary tool in assessing weight status and identifying potential obesity risks in children. But, a growing body of research, including a new study published in The Journal of Nutrition, suggests that relying solely on BMI can be misleading. The study, analyzing data from over 2,400 children and adolescents in the U.S., reveals a disconnect between BMI and a more accurate measure of body fat: waist-to-height ratio (WHtR).

View this post on Instagram about Obesity, Nutrition
From Instagram — related to Obesity, Nutrition

The BMI Puzzle: Lean Tissue vs. Fat

BMI, calculated from height and weight, doesn’t differentiate between muscle and fat mass. This is particularly problematic in children, whose bodies are undergoing rapid changes in composition. The new research highlights that the typical “adiposity rebound” – the point around age 6 when BMI starts to rise after an initial decline – may not signify an increase in body fat. Instead, it could reflect healthy growth in lean tissues like muscle and bone.

Researchers found that while BMI followed the expected pattern, WHtR continued to decrease during the same period. This suggests that the BMI increase is not necessarily indicative of increased adiposity. This finding challenges the long-held belief that an early adiposity rebound automatically signals a higher risk of future obesity.

Waist-to-Height Ratio: A More Precise Indicator

WHtR, which compares waist circumference to height, provides a more accurate assessment of abdominal fat – a key indicator of metabolic health risks like heart disease, type 2 diabetes, and high blood pressure. Because it’s less influenced by muscle mass, WHtR offers a clearer picture of a child’s body composition.

The study describes this phenomenon as a “body composition reset,” where the BMI increase coincides with a continued decrease in WHtR, indicating a shift towards healthy lean tissue development. This supports the idea that focusing solely on BMI can lead to misclassifying normal growth patterns as obesity risk.

Global Shift Towards WHtR and the Future of Pediatric Obesity Assessment

The findings align with recent global consensus statements advocating for a more comprehensive approach to obesity diagnosis. Experts now recommend using WHtR, alongside BMI, to confirm obesity diagnoses, particularly in children. Andrew Agbaje, lead author of the study, emphasizes that “obesity should not be diagnosed with BMI alone but confirmed with non-invasive measures such as waist-to-height ratio.”

U of M experts weigh in on changes in childhood BMI growth

This shift in perspective has significant implications for clinical practice. Healthcare providers may need to reconsider how they interpret BMI data in children and incorporate WHtR as a routine screening tool. This could aid avoid unnecessary interventions based on inaccurate assessments.

Did you know? Andrew Agbaje was recently awarded the inaugural American Society for Nutrition Foundation-Novo Nordisk Foundation Flemming Quaade Award for Innovative Approaches to Childhood Obesity, recognizing his contributions to this evolving field.

Beyond WHtR: Emerging Technologies and Personalized Approaches

While WHtR represents a significant improvement over BMI, research continues to explore even more precise methods for assessing body composition. Technologies like bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DEXA) can provide detailed measurements of body fat, muscle mass, and bone density. However, these methods are often more expensive and less accessible than WHtR.

Beyond WHtR: Emerging Technologies and Personalized Approaches
Obesity Childhood Approaches

The future of pediatric obesity assessment likely lies in personalized approaches that combine multiple data points, including WHtR, genetic information, lifestyle factors, and metabolic markers. This will allow healthcare providers to tailor interventions to each child’s unique needs and risk factors.

FAQ

Q: What is adiposity rebound?
A: Adiposity rebound is the point in childhood, typically around age 6, when BMI starts to rise again after an initial decline.

Q: Why is BMI not always accurate?
A: BMI doesn’t distinguish between fat mass and lean tissue, which can be misleading in children whose bodies are rapidly changing.

Q: What is waist-to-height ratio (WHtR)?
A: WHtR is a measure of abdominal fat calculated by dividing waist circumference by height. It’s a more accurate indicator of body fat than BMI.

Q: Should parents be concerned if their child experiences an early adiposity rebound?
A: Not necessarily. The new research suggests that an early rebound doesn’t automatically mean a child is at risk for obesity. It’s important to consider other factors, such as WHtR and overall health.

Pro Tip: Focus on promoting healthy habits – a balanced diet, regular physical activity, and adequate sleep – rather than solely fixating on weight or BMI.

Want to learn more about childhood nutrition and healthy weight management? Explore resources from the American Society for Nutrition.

April 16, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Waist-to-height ratio outperforms BMI in predicting hypertension risk

by Chief Editor April 15, 2026
written by Chief Editor

Waist-to-Height Ratio: A New Standard for Assessing Cardiovascular Risk?

For decades, Body Mass Index (BMI) has been the proceed-to metric for assessing weight and related health risks. But, a groundbreaking new study from the University of Eastern Finland and Robert Wood Johnson Medical School at Rutgers University suggests a more precise tool may be on the horizon: the waist-to-height ratio (WHtR). Research indicates that WHtR is a stronger predictor of hypertension than BMI, potentially revolutionizing how we screen for cardiovascular disease.

The Limitations of BMI

BMI, while widely used, has well-documented limitations. It fails to differentiate between fat mass and muscle mass. A muscular individual may be classified as “overweight” or even “obese” based on BMI, despite having a low percentage of body fat and a reduced risk of cardiometabolic diseases. This can lead to misdiagnosis and inappropriate health recommendations.

The Limitations of BMI

Why Waist-to-Height Ratio Matters

The WHtR offers a more nuanced assessment by measuring central obesity – the accumulation of fat around the abdomen. This type of fat is particularly linked to increased risk of heart disease, type 2 diabetes, and other health problems. A commonly recommended cut-off of WHtR 0.5 has been suggested by the UK National Institute for Clinical Excellence (NICE) to diagnose central obesity.

Study Findings: WHtR Outperforms BMI

The recent study, utilizing data from the US National Health and Nutrition Examination Survey (NHANES) spanning 2015-2023 and including over 19,000 participants, revealed compelling results. Individuals with high or excess fat mass as determined by WHtR were significantly more likely to have elevated blood pressure and hypertension. Specifically, those with excess fat had a 161% higher likelihood of hypertension. Interestingly, while BMI was associated with elevated blood pressure, it didn’t present a consistent link to hypertension itself.

Dr. Mahidere Ali, lead author of the study, emphasized that “BMI failed to detect the independent effect of adiposity, likely because it does not isolate the confounding influence of muscle mass.”

Implications for Public Health and Future Trends

These findings suggest a potential shift in how healthcare professionals assess cardiovascular risk. The simplicity and scalability of WHtR make it an attractive alternative or supplement to BMI. A WHtR calculator is available at https://urfit-child.com/waist-height-calculator/.

Looking ahead, we can anticipate several trends:

  • Increased Adoption of WHtR in Clinical Settings: More doctors may begin incorporating WHtR into routine check-ups, particularly for individuals at risk of cardiovascular disease.
  • Personalized Health Recommendations: WHtR can help tailor health recommendations based on an individual’s specific body composition and risk factors.
  • Refined Cut-off Points: Further research may refine WHtR cut-off points for different populations and age groups to maximize its accuracy.
  • Integration with Wearable Technology: WHtR could be integrated into wearable fitness trackers and health apps, providing individuals with real-time feedback on their cardiovascular risk.

WHtR in Youth: A Promising Indicator

The study similarly showed promising results in younger populations. While the association between WHtR and hypertension wasn’t statistically significant in those under 25 (likely due to the lower prevalence of hypertension in this age group), WHtR-assessed high and excess fat increased the likelihood of elevated blood pressure by 66% and 98%, respectively.

Rutgers School of Medicine: A Hub for Cardiovascular Research

The Robert Wood Johnson Medical School at Rutgers University, a key partner in this research, is poised to become a major force in medical education and research. As part of the future Rutgers School of Medicine, with anticipated accreditation in 2027, the institution will continue to drive innovation in cardiovascular health and other critical areas of medicine.

Frequently Asked Questions

What is WHtR?
Waist-to-height ratio is a measurement calculated by dividing your waist circumference by your height. It’s a simple way to assess central obesity.

How do I calculate my WHtR?
Measure your waist circumference and your height (in the same units). Then, divide your waist measurement by your height.

What is a healthy WHtR?
A WHtR of less than 0.5 is generally considered healthy. A WHtR of 0.5 or higher may indicate increased risk of health problems.

Is WHtR a replacement for BMI?
Not necessarily, but it offers a more nuanced assessment of cardiovascular risk. It’s best to discuss both measurements with your healthcare provider.

Where can I locate more information about this study?
You can find the study published in The Journal of Nutrition: https://doi.org/10.1016/j.tjnut.2026.101426

Pro Tip: Focus on a holistic approach to health, including a balanced diet, regular exercise, and stress management, alongside monitoring your WHtR.

Did you know? Increased muscle mass can actually *reduce* your risk of cardiometabolic diseases, highlighting the limitations of relying solely on BMI.

Have you discussed your WHtR with your doctor? Share your thoughts and experiences in the comments below!

April 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Alzheimer’s risk gene APOE4 impacts bone health in females

by Chief Editor April 14, 2026
written by Chief Editor

The Silent Threat: Alzheimer’s Gene Linked to Hidden Bone Loss in Women

A groundbreaking study from the Buck Institute for Research on Aging has revealed a surprising connection between APOE4, the most common genetic risk factor for Alzheimer’s disease, and a decline in bone quality specifically in women. This discovery, published in Advanced Science, suggests that bone health could serve as an early warning system for cognitive decline, potentially years before symptoms manifest.

The Invisible Impact on Bone

Researchers found that APOE4 disrupts bone at a molecular level, impacting osteocytes – the cells responsible for maintaining bone strength – in a way that standard bone scans cannot detect. This is particularly concerning as physicians have long observed a higher rate of bone fractures in individuals with Alzheimer’s, and osteoporosis in women is known to be an early predictor of the disease. The study focused on female mice, revealing that APOE4 suppresses perilacunar/canalicular remodeling, the process osteocytes use to keep bone resilient.

Proteomic Analysis Uncovers a Hidden Link

The research team, led by Charles Schurman, PhD, utilized a proteomic analysis of aged mouse bone to identify a surprising abundance of proteins associated with neurological disease, including apolipoprotein E (APOE) and amyloid precursor protein, within the bone tissue. Notably, APOE expression in osteocytes was twice as high in aged female mice compared to younger or male mice. Further analysis using a humanized mouse model carrying different APOE variants (APOE2, APOE3, and APOE4) showed that APOE4 had strong, sex-specific effects on both bone and hippocampal tissue.

Proteomic Analysis Uncovers a Hidden Link

Why Women Are Particularly Vulnerable

The study highlights a critical sex-specific effect. The disruption at the protein level in bone was more pronounced than changes observed in the hippocampus, the brain region heavily involved in memory, and learning. This finding aligns with epidemiological data showing that women are disproportionately affected by both Alzheimer’s disease and osteoporosis.

Implications for Early Diagnosis and Treatment

Osteocytes as Early Sentinels

According to Professor Lisa Ellerby, PhD, a senior author of the study, these results suggest osteocytes could act as “early biological sentinels” for age-related cognitive decline in women carrying the APOE4 gene. This opens the door for potential new diagnostic approaches that focus on assessing osteocyte function as a predictor of future cognitive impairment.

Future Research and Therapeutic Targets

The research team believes that targeting osteocyte function could offer a novel strategy for preserving bone quality in women at risk for Alzheimer’s. Further investigation is needed to determine if these findings translate to humans and to identify specific interventions that can protect both bone and brain health. The study emphasizes the importance of viewing the body as an interconnected system, rather than isolating organs and diseases.

What Does This Mean for You?

While this research is still in its early stages, it offers a new perspective on the complex relationship between brain and bone health. For women, particularly those with a family history of Alzheimer’s or osteoporosis, maintaining bone health through diet, exercise, and regular check-ups may be even more critical than previously understood.

Did you know?

A diagnosis of osteoporosis in women is the earliest known predictor for Alzheimer’s disease.

FAQ

  • What is APOE4? APOE4 is a genetic variation that significantly increases the risk of developing Alzheimer’s disease.
  • How does APOE4 affect bone health? APOE4 disrupts the function of osteocytes, leading to a decline in bone quality that is not detectable by standard imaging.
  • Are men affected by this? The study specifically found that these effects are more pronounced in female mice.
  • Could this lead to new treatments? Researchers believe targeting osteocyte function could offer a new approach to preserving bone quality and potentially slowing cognitive decline.

Stay informed about the latest research on Alzheimer’s and osteoporosis. Explore the Buck Institute for Research on Aging website for more information.

April 14, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Natural peptide PEPITEM shows promise in reducing arthritic joint swelling

by Chief Editor April 13, 2026
written by Chief Editor

PEPITEM: A Potential Game-Changer in Arthritis Treatment?

New research suggests a naturally occurring immunopeptide, PEPITEM, could offer a significant advancement in the treatment of inflammatory arthritis, potentially rivaling current standard-of-care options. Scientists at the University of Birmingham, who initially discovered PEPITEM and characterized the Adiponectin-PEPITEM pathway, have demonstrated promising results in both human and animal studies.

Understanding the Adiponectin-PEPITEM Pathway

The Adiponectin-PEPITEM pathway plays a crucial role in regulating immune function and the movement of immune cells throughout the body. This pathway maintains a delicate balance between activating and suppressing the immune system. In a healthy state, adiponectin stimulates white blood cells to produce PEPITEM, which then reduces their migration into tissues, preventing an overactive inflammatory response.

How Arthritis Disrupts the Pathway

In inflammatory arthritis, including rheumatoid arthritis (RA) and psoriatic arthritis (PsA), this natural regulatory process breaks down. White blood cells become less responsive to adiponectin and produce less PEPITEM, leading to uncontrolled inflammation and joint damage. Researchers found a reduced capacity of white blood cells to respond to adiponectin in patients with suspected inflammatory arthritis, a deficiency that could be restored with PEPITEM supplementation.

How Arthritis Disrupts the Pathway

Promising Results from Pre-Clinical and Human Studies

The recent study, published in Arthritis & Rheumatology, investigated the efficacy of PEPITEM in addressing this dysregulation. Results showed that injecting synthetic PEPITEM into animal models of inflammatory and gouty arthritis could prevent the onset of the disease and significantly reduce joint swelling – achieving results comparable to infliximab, a current standard treatment. Tissue analysis revealed less inflammation, cartilage damage, and bone erosion in PEPITEM-treated mice.

Molecular studies further demonstrated that PEPITEM treatment led to a decrease in inflammatory mediators (NF-kB and COX2 protein) and an increase in foxp3, a key component in immune-suppressing white blood cells.

A Safer Alternative?

Professor Helen McGettrick of the University of Birmingham highlights a potential advantage of PEPITEM: “There could be significant benefits over existing therapies, which are immunosuppressive in otherwise healthy populations. The risk of toxicity from a natural peptide is extremely low, and administration in early disease could reduce reliance on steroids in the earliest phases of rheumatoid arthritis and psoriatic arthritis.”

Beyond Arthritis: PEPITEM’s Expanding Potential

This isn’t the first indication of PEPITEM’s broad therapeutic potential. Previous research has suggested its promise in bone repair, enhancing bone mineralisation and strength, and even reversing bone loss. The researchers note that existing Disease-Modifying Anti-Rheumatic Drugs (DMARDs) don’t reverse joint damage, even when inflammation is well-controlled.

Beyond Arthritis: PEPITEM’s Expanding Potential

Future Trends and Implications

The success of PEPITEM in pre-clinical models opens doors for several exciting future trends in arthritis treatment:

  • Early Intervention: PEPITEM’s potential to restore immune regulation suggests it could be particularly effective when administered early in the disease process, potentially preventing irreversible joint damage.
  • Personalized Medicine: Identifying patients with deficiencies in the Adiponectin-PEPITEM pathway could allow for targeted PEPITEM supplementation, maximizing treatment efficacy.
  • Combination Therapies: Exploring the synergistic effects of PEPITEM with existing DMARDs could lead to more comprehensive and effective treatment strategies.
  • Broader Applications: Given PEPITEM’s role in regulating immune function, research may expand to investigate its potential in other autoimmune diseases, such as type 1 diabetes and lupus.

Did you understand?

PEPITEM was initially identified as a protective agent against inflammageing – the chronic, low-grade inflammation associated with aging – suggesting potential benefits beyond arthritis.

FAQ

Q: What is PEPITEM?
A: PEPITEM is a naturally occurring immunopeptide that helps regulate immune function and reduce inflammation.

Q: How does PEPITEM work?
A: PEPITEM reduces the migration of white blood cells into tissues, preventing an overactive inflammatory response.

Q: Is PEPITEM currently available as a treatment?
A: No, PEPITEM is still under investigation and is not yet available as a standard treatment for arthritis.

Q: What types of arthritis could PEPITEM potentially treat?
A: Research suggests PEPITEM could be effective in treating inflammatory arthritis, including rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Pro Tip: Maintaining a healthy lifestyle, including a balanced diet and regular exercise, can support overall immune function and potentially complement future PEPITEM-based therapies.

Stay informed about the latest advancements in arthritis research. Explore more news from the University of Birmingham to learn about ongoing studies and potential breakthroughs.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study reveals how hyperdiploidy creates rare pre-leukemic clones in children

by Chief Editor April 8, 2026
written by Chief Editor

Unraveling the Mystery of Childhood Leukemia: How Extra Chromosomes May Hold the Key to Prevention

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, and a fresh study published in Cell Reports sheds light on the complex origins of this disease. Researchers have discovered that the presence of extra chromosomes – a condition known as hyperdiploidy – doesn’t directly cause leukemia, but instead creates a state of cellular instability that can pave the way for its development years later.

The Two-Stage Origin of Childhood B-ALL

The research, led by scientists at the University of Barcelona and the Josep Carreras Leukemia Research Institute, proposes a two-stage model. The first stage, occurring in utero, involves the development of hyperdiploidy. This initial phase doesn’t immediately trigger cancer, but establishes a population of cells with chromosomal abnormalities. The second stage, occurring postnatally, requires unknown factors to initiate the malignant transformation of these rare, pre-leukemic clones.

View this post on Instagram

This suggests a potential window of vulnerability between two and six years of age, coinciding with the peak incidence of childhood lymphoblastic leukemia. Understanding what triggers the transition from pre-leukemic clones to full-blown disease is now a critical focus for researchers.

Hyperdiploidy: A Paradoxical Role in Leukemia Development

Hyperdiploidy is characterized by an excess of chromosomes, with a typical chromosome count ranging from 51 to 63 in B-ALL patients, compared to the normal 46. Specific chromosomes are frequently duplicated, including chromosomes 4, 6, 10, 14, 17, 18, 21, and the X chromosome. The study reveals that this chromosomal gain isn’t random, but rather a specific pattern that arises during fetal development in early hematopoietic progenitor stem cells – the cells responsible for generating blood cells.

Interestingly, the study found that hyperdiploidy actually reduces the proliferative capacity of cells and delays their differentiation. This means the cells divide less frequently and accept longer to mature. Although, this instability also allows these cells to persist as rare clones in the bone marrow, potentially for years, without immediately causing leukemia. This phenomenon is known as the “aneuploidy paradox,” where chromosomal changes can be detrimental to normal cells but facilitate tumor progression in certain contexts.

Advanced Technologies Unlocking New Insights

The researchers utilized cutting-edge technologies to reach these conclusions. Single-cell whole-genome sequencing (scWGS) allowed for precise analysis of the chromosomal content of individual cells. Xenograft models using immunodeficient mice were used to observe how pre-leukemic clones behave in a living organism. High-throughput confocal microscopy, combined with custom-developed computer macros, enabled the automated examination of thousands of cells at high resolution.

A key element of the study was the use of human fetal hematopoietic stem cells, a rare and valuable biological sample provided by the UK Medical Research Council. This allowed researchers to directly study the cells where the initial alterations associated with pediatric leukemia originate.

Future Trends and Potential Prevention Strategies

Although B-ALL now has a high cure rate (80-90%) thanks to combination chemotherapy, stem cell transplantation, and immunotherapy, the long-term goal is prevention. The findings suggest several potential avenues for future research:

  • Early Detection of Pre-Leukemic Clones: Developing methods to identify and monitor these rare clones in newborns could allow for early intervention.
  • Understanding Triggering Factors: Identifying the postnatal factors that initiate malignant transformation is crucial. Could common infections, environmental exposures, or genetic predispositions play a role?
  • Targeted Therapies: Developing therapies that specifically target the vulnerabilities of hyperdiploid cells, potentially preventing them from evolving into leukemia.

The refinement of hyperdiploidy definitions, as demonstrated by research at St. Jude Children’s Research Hospital, is also critical. Standardizing these definitions will ensure consistent care and more accurate prediction of patient outcomes.

Did you know?

Hyperdiploidy is the most common genetic abnormality in childhood B-ALL, accounting for 25-35% of cases and is generally associated with a favorable prognosis.

FAQ

Q: What is hyperdiploidy?
A: Hyperdiploidy is a genetic condition where cells have more chromosomes than usual. It’s common in childhood B-ALL.

Q: Does hyperdiploidy always lead to leukemia?
A: No, hyperdiploidy creates a pre-leukemic state, but additional factors are needed to trigger the development of full-blown leukemia.

Q: What is the two-stage model of B-ALL development?
A: The first stage is the development of hyperdiploidy in utero, and the second stage is the postnatal transformation of pre-leukemic clones into leukemia.

Q: What technologies were used in this study?
A: Researchers used single-cell whole-genome sequencing, xenograft models, and high-throughput confocal microscopy.

Pro Tip: Staying informed about the latest research in childhood leukemia is crucial for parents, and caregivers. Consult with a pediatric oncologist for personalized advice and treatment options.

Want to learn more about childhood cancer research? Visit St. Jude Children’s Research Hospital to explore their ongoing studies and support their mission.

April 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Estradiol patches as effective as injections for locally advanced prostate cancer

by Chief Editor March 26, 2026
written by Chief Editor

Prostate Cancer Treatment: Patches Offer Hope for Fewer Side Effects

Men diagnosed with locally advanced prostate cancer may soon have a more convenient and potentially less debilitating treatment option. A recent clinical trial led by University College London (UCL) researchers has demonstrated that hormone patches are as effective as traditional injections in controlling the disease, whereas significantly reducing common side effects.

How Hormone Therapy Works

Hormone therapy is a mainstay in treating prostate cancer that has spread beyond the prostate gland. It works by suppressing testosterone, a hormone that fuels cancer growth. Traditionally, this has been achieved through injections of drugs that block testosterone production – LHRH agonists.

The Promise of Estradiol Patches

The new study, published in The New England Journal of Medicine, explored an alternative: estradiol patches, the same type used in hormone replacement therapy for women experiencing menopause. These patches deliver oestrogen through the skin, which in turn lowers testosterone levels.

Trial Results: Comparable Effectiveness, Reduced Side Effects

The trial involved 1,360 men with locally advanced prostate cancer. After three years or more, researchers found that 87% of those using estradiol patches were alive without their cancer spreading, compared to 86% in the group receiving injections. This demonstrates comparable effectiveness.

However, the benefits extend beyond efficacy. Side effects commonly associated with injections, such as hot flushes, bone density problems, and increased risk of heart disease, were considerably less frequent among men using the patches. While breast tissue swelling (gynecomastia) was more common with the patches, many patients may find this a more manageable side effect.

Convenience and Quality of Life

Beyond fewer side effects, estradiol patches offer a significant convenience advantage. Unlike injections, which require multiple hospital or GP visits, the patches can be easily applied by patients at home. This ease of administration, coupled with the improved side effect profile, is expected to enhance patients’ quality of life.

Current Status and Future Outlook

Currently, estradiol patches are not licensed in the UK specifically for prostate cancer treatment. They are being used “off-label,” meaning doctors can prescribe them for this purpose, but some healthcare providers may be hesitant. UCL Business Ltd is actively working to secure licensing approval, potentially through extending existing licenses for the patches’ use in hormone replacement therapy.

Expert Perspectives

Professor Ruth Langley, lead author of the study, believes the findings should empower men with prostate cancer to choose the treatment that best suits their needs. Simon Grieveson, Assistant Director of Research at Prostate Cancer UK, highlighted the potential for greater patient choice and improved treatment adherence. Caroline Geraghty, senior specialist nurse manager at Cancer Research UK, emphasized the importance of finding treatments that are not only effective but similarly kinder to patients.

UK Prostate Cancer Statistics

Prostate cancer is the most commonly diagnosed cancer in the UK, affecting one in eight men during their lifetime. Over 64,000 men are diagnosed annually, with around 12,000 deaths each year. Approximately 540,000 men in the UK are currently living with or after a prostate cancer diagnosis.

Did you know?

The estradiol patches used in this trial are the same as those used to manage menopause symptoms in women.

FAQ

  • Are estradiol patches widely available for prostate cancer treatment? No, they are currently not licensed for this purpose in the UK and are being used “off-label.”
  • What are the main side effects of traditional hormone therapy injections? Common side effects include hot flushes, bone density problems, and increased risk of heart disease.
  • Is this treatment suitable for all stages of prostate cancer? This study focused on men with locally advanced, non-metastatic prostate cancer.
  • How does this treatment compare in terms of effectiveness? The trial showed that estradiol patches were as effective as injections in preventing cancer from spreading.

Pro Tip: Discuss all treatment options and potential side effects with your doctor to create an informed decision that aligns with your individual needs and preferences.

Learn more about prostate cancer and available treatments at Cancer Research UK and Prostate Cancer UK.

Have questions about prostate cancer treatment? Share your thoughts in the comments below!

March 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Jeff Hafley: Malik Willis Must Prioritize Performance Over Leadership

    May 23, 2026
  • Beyond Ebola: Emerging Outbreaks in the DRC

    May 23, 2026
  • Enceladus: Sampling an Alien Ocean Without Landing

    May 23, 2026
  • Two Aides Killed in Fatal Car Crash Involving Lawmaker Gus Hilman

    May 23, 2026
  • Unleashing Feminine Fury: The Revolutionary History of the Babushka Drum and the Women’s Liberation Movement

    May 23, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World